Comparative Pharmacokinetic (PK) Study of Ibuprofen and Diphenhydramine Hydrochloride MR Tablets in Healthy Adults Under Fasting Condition

Pain Clinical Trial

Official title:

An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Two-way Crossover, Oral Comparative Pharmacokinetic (PK) Study of Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets, 400mg/50mg of Overseas Pharmaceuticals, Ltd. With Motrin IB (Ibuprofen Tablets USP 200mg (2× 200mg)) and BENADRYL (Diphenhydramine Hydrochloride Tablet 25 mg(2×25 mg)), Distributed by - Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division in Normal Healthy, Adult, Human Subjects Under Fasting Condition.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05729555
• Other study ID #: YYKQ-202210
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: April 3, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: February 2023
• Source: Overseas Pharmaceuticals, Ltd.
• Contact: Dr. Huaihan Cai, Director of Medical Affairs
• Phone: 0086-18352616957
• Email: caihuaihan[@]overseaspharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets were randomized, open, two-cycle Comparative pharmacokinetic test under double crossover and fasting condition. Main objective: Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets developed by Overseas Pharmaceuticals, Ltd.(Specification: each tablet containing ibuprofen 400 mg, Phenhenhydramine hydrochloride 50 mg) is the test preparation, JOHNSON & JOHNSON CONSUMER INC. Production (trade name: Motrin IB®, Specification: 200 mg) for comparative drug product 1, JOHNSON & JOHNSON CONSUMER INC. Hydrodramine hydrochloride (trade name: Benadryl®, Specification: 25 mg) for comparative formulation 2, In the fasting state, To investigate the pharmacokinetic parameters in healthy Chinese subjects of 1 and 2, And were compared. Secondary objective: To evaluate the safety of a single oral administration of Ibuprofen and Diphenhydramine Hydrochloride Modified-Release Tablets and reference 1 and reference 2 diphenhydramine hydrochloride tablets in fasting conditions in healthy Chinese subjects.

Description:

Subjects were randomized in a 1:1 ratio to one of 2 T-R (R-T). That is, 8 subjects in the first cycle T group had fasting 1 tablet of test preparation (compound ibuprofen polyrelease tablet, specification: each containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg, Overseas Pharmaceuticals, Ltd.; 8 subjects in the R group had fasting 1 ibuprofen tablet (200 mg) and 2 tablets of diphenhydramine hydrochloride (25 mg) with 240 ml warm water. Cross-administration after 7 days. The 16 healthy subjects (including male and female subjects) were randomly divided into 2 groups, T-R and R-T, with 8 participants each. The selected subjects were admitted to the phase I ward of the clinical research center 1 day before each cycle and fasted for more than 10h before each cycle. At 0 h (within 1.0 h before administration) and 5 min, 15 min, 30 min, 45 min, 1.0 h, 1.25 h, 1.5 h, 2.0 h, 2.5 h, 3.0 h, 3.5 h, 4.0 h, 4.5 h, 5.0 h, 5.5 h, 6.0 h, 7.0 h, 8.0 h, 9.0 h, 10.0 h, 12.0 h, 24.0 h, 36.0 h, and 48.0 h, Upper limb venous blood was collected at 25 time points, About 1.0 mL blood was discarded before each blood samples using intravenous indwelling needle, After each blood collection, About 4 mL of blood was collected into vacuum labeled EDTA-K2 anticoagulant. The seated vital signs (including temperature, pulse, and blood pressure) were measured at 0 h before administration (within 1.0 h before administration) and 2.0 ± 0.5 h, 8.0 ± 0.5 h, 24.0 ± 1.0 h, 48.0 ± 1.0 h after administration. The subjects had a physical examination, vital signs, electrocardiogram and laboratory tests after the blood sampling. Medical staff during the study to observe and ask the subjects about subjective feelings and possible adverse events during the trial. If a subject has an AE during the study, the investigator should follow up the AE as far as possible until the adverse event response, or return to the screening period level, or the subject has stable condition.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 16
• Est. completion date: December 31, 2023
• Est. primary completion date: October 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject was fully informed of the trial purpose, nature, methods, and possible adverse effects, voluntarily acted as the subject, and signed the informed consent form prior to the start of any study procedures.

2. Healthy subjects aged 18 years or older (including 18 years old), both male and female.

3. Male weight was 50.0 kg and female weight 45.0 kg; body mass index (BMI) was within the range of 19.0 to 26.0 kg/m2 (including the cut-off value).

4. There is no birth plan and voluntary appropriate and effective contraceptive measures between the signing of the informed consent form and within 6 months after the end of the study, and no sperm donation and egg donation plan.

5. The subject was able to communicate well with the investigator and to understand and comply with the requirements of this study.

Exclusion Criteria:

1. Allergic constitution or a history of clinically significant food, drug allergy, or other allergic diseases (asthma, urticaria, eczematous dermatitis, etc.); or allergic to any component of ibuprofen or diphenhydramine; or a history of asthma or other allergic reactions after taking aspirin or other non-steroidal anti-inflammatory drugs; or allergic to ethanolamine drugs.

2. People with active upper gastrointestinal ulcer/bleeding, asthma history, or history of myasthenia gravis, angle-closure glaucoma, and prostatic hypertrophy

3. Patients with poor vascular puncture conditions, or unable to tolerate venipuncture, or a history of blood halo.

4. There are clinically meaningful diseases of cardiovascular, blood, liver, kidney, endocrine, respiratory, digestive, divine, menstrual, mental, mental, immune, skin and metabolic disorders, which are considered meaningful by the investigator, or a chronic or serious medical history of these diseases; or a surgical history that may affect the absorption and metabolism of drugs.

5. Patients with abnormal physical examination, vital signs examination, 12-lead electrocardiogram and laboratory examination, and abnormal clinical significance as judged by the study doctor.

6. human immunodeficiency virus (HIV) antibody, or hepatitis B virus surface antigen (HBsAg), or hepatitis C virus (HCV) antibody, or treponema pallidum antibody (anti-TP) test results are positive.

7. Women, pregnant, lactating, or women of childbearing age with unprotected sex or positive pregnancy test results within 14 days prior to planned drug administration.

8. , those who were vaccinated within 3 months before the screening (except COVID-19 vaccine), or who received COVID-19 vaccine within 1 week before the screening or who planned to receive any vaccine during the trial or 1 week after the end of the study;

9. or who donated 400 mL or received blood products or intended to donate blood (including blood components) during the trial or within 3 months after the end of the trial.

Related Conditions & MeSH terms

• Insomnia
• Pain

Intervention

Drug:
• Compound ibuprofen polyrelease tablets
Specification: Each tablet containing ibuprofen 400 mg, diphenhydramine hydrochloride 50 mg Batch number: 22082801 Content: Ibuprofen 96.9%, diphenhydramine hydrochloride 102.4% Effective: August 27,2024 S torage conditions: sealed, room temperature. Manufacturers: Overseas Pharmaceuticals, Ltd. Usage and dosage:Once a day, one tablet at a time
• reference 1 (R1): Ibuprofen Tablets (Motrin IB®)reference 2 (R2): Diphenhydramine Hydrochloride Tablets (Benadryl®)
Specification: 200 mg Batch number: 2CE2330 Content: 100.5% Expiry date: December 2023 Storage conditions; Storage in 20? -25? manufacturer: JOHNSON & JOHNSON CONSUMER INC. Usage and dosage:Once a day, two tablets at a time Specification: 25 mg Batch number: BCC009 Content: 99.2% Effective to: December 2023 storage conditions; storage at 20? -25?, shading manufacturer: JOHNSON & JOHNSON CONSUMER INC Usage and dosage:Once a day, two tablets at a time

Locations

Country	Name	City	State
China	Zhujiang Hospital of Southern Medical University	Guangzhou	Guangdong

Sponsors (2)

Lead Sponsor	Collaborator
Overseas Pharmaceuticals, Ltd.	Guangzhou Kangqi Medical Technology Co., LTD

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the curve from time zero to the time of the last quantifiable plasma concentration of the period (AUC0-last)	The 90% CI for the geometric mean ratios (i.e., antilog-transformation for 90% CI of difference with log transformation) of AUC0-last within [0.8, 1.25] range will be used to determine the result of bioequivalence.	1 month
Primary	Area under the curve from time zero to infinity (AUC0-inf)	The 90% CI for the geometric mean ratios (i.e., antilog-transformation for 90% CI of difference with log transformation)of AUC0-inf within [0.8, 1.25] range will be used to determine the result of bioequivalence.	1 month
Primary	Peak concentration at each treatment period (Cmax,tp)	The 90% CI for the geometric mean ratios (i.e., antilog-transformation for 90% CI of difference with log transformation)of Cmax,tp within [0.8, 1.25] range will be used to determine the result of bioequivalence.	1 month
Secondary	Peak concentration of the first dosing (Cmax)	Individual felodipine plasma concentration-time profile for each treatment period will be established.	1 month
Secondary	Time to reach peak concentration of the first dosing (Tmax)	Individual felodipine plasma concentration-time profile for each treatment period will be established.	1 month
Secondary	Terminal half-life (T1/2)	Individual felodipine plasma concentration-time profile for each treatment period will be established.	1 month
Secondary	Mean residence time (MRT)	Individual felodipine plasma concentration-time profile for each treatment period will be established.	1 month